Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.
Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.
Market Analysis and Insights: Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market
The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market is projected to grow from US$ 17720 million in 2024 to US$ 56720 million by 2030, at a Compound Annual Growth Rate (CAGR) of 21.4% during the forecast period.
The major players in global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market include Janssen, Qiagen, Advanced Cell Diagnostics, etc. North America and Europe are main markets, they occupy about 65% of the global market. CellSearch is the main type, with a share about 70%. Breast Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment are main applications, which hold a share about 60%.
Report Covers:
This report presents an overview of global market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Janssen
Qiagen
Advanced Cell Diagnostics
ApoCell
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Fluidigm
Ikonisys
AdnaGen
IVDiagnostics
Miltenyi Biotec
ScreenCell
Silicon Biosystems
Segment by Type
CellSearch
Others
Segment by Application
Breast Cancer Diagnosis and Treatment
Prostate Cancer Diagnosis and Treatment
Colorectal Cancer Diagnosis and Treatment
Lung Cancer Diagnosis and Treatment
Other Cancers Diagnosis and Treatment
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 CellSearch
1.2.3 Others
1.3 Market by Application
1.3.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Breast Cancer Diagnosis and Treatment
1.3.3 Prostate Cancer Diagnosis and Treatment
1.3.4 Colorectal Cancer Diagnosis and Treatment
1.3.5 Lung Cancer Diagnosis and Treatment
1.3.6 Other Cancers Diagnosis and Treatment
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Perspective (2019-2030)
2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Growth Trends by Region
2.2.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Historic Market Size by Region (2019-2024)
2.2.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size by Region (2025-2030)
2.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Dynamics
2.3.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Trends
2.3.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Drivers
2.3.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Challenges
2.3.4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) by Players
3.1.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Players (2019-2024)
3.1.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Players (2019-2024)
3.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Concentration Ratio
3.4.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue in 2023
3.5 Global Key Players of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Head office and Area Served
3.6 Global Key Players of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), Product and Application
3.7 Global Key Players of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Breakdown Data by Type
4.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Historic Market Size by Type (2019-2024)
4.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size by Type (2025-2030)
5 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Breakdown Data by Application
5.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Historic Market Size by Application (2019-2024)
5.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2019-2030)
6.2 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type
6.2.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type (2019-2024)
6.2.2 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type (2025-2030)
6.2.3 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Type (2019-2030)
6.3 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application
6.3.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application (2019-2024)
6.3.2 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application (2025-2030)
6.3.3 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Application (2019-2030)
6.4 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country
6.4.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2019-2024)
6.4.3 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2019-2030)
7.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type
7.2.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type (2019-2024)
7.2.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type (2025-2030)
7.2.3 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Type (2019-2030)
7.3 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application
7.3.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application (2019-2024)
7.3.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application (2025-2030)
7.3.3 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Application (2019-2030)
7.4 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country
7.4.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2019-2024)
7.4.3 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2019-2030)
8.2 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type
8.2.1 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type (2019-2024)
8.2.2 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type (2025-2030)
8.2.3 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Type (2019-2030)
8.3 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application
8.3.1 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application (2019-2024)
8.3.2 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application (2025-2030)
8.3.3 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2019-2030)
9.2 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type
9.2.1 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type (2019-2024)
9.2.2 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type (2025-2030)
9.2.3 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Type (2019-2030)
9.3 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application
9.3.1 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application (2019-2024)
9.3.2 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application (2025-2030)
9.3.3 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Application (2019-2030)
9.4 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region
9.4.1 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region (2019-2024)
9.4.3 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type
10.2.1 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application
10.3.1 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country
10.4.1 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Janssen
11.1.1 Janssen Company Details
11.1.2 Janssen Business Overview
11.1.3 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.1.4 Janssen Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.1.5 Janssen Recent Developments
11.2 Qiagen
11.2.1 Qiagen Company Details
11.2.2 Qiagen Business Overview
11.2.3 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.2.4 Qiagen Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.2.5 Qiagen Recent Developments
11.3 Advanced Cell Diagnostics
11.3.1 Advanced Cell Diagnostics Company Details
11.3.2 Advanced Cell Diagnostics Business Overview
11.3.3 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.3.4 Advanced Cell Diagnostics Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.3.5 Advanced Cell Diagnostics Recent Developments
11.4 ApoCell
11.4.1 ApoCell Company Details
11.4.2 ApoCell Business Overview
11.4.3 ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.4.4 ApoCell Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.4.5 ApoCell Recent Developments
11.5 Biofluidica
11.5.1 Biofluidica Company Details
11.5.2 Biofluidica Business Overview
11.5.3 Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.5.4 Biofluidica Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.5.5 Biofluidica Recent Developments
11.6 Clearbridge Biomedics
11.6.1 Clearbridge Biomedics Company Details
11.6.2 Clearbridge Biomedics Business Overview
11.6.3 Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.6.4 Clearbridge Biomedics Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.6.5 Clearbridge Biomedics Recent Developments
11.7 CytoTrack
11.7.1 CytoTrack Company Details
11.7.2 CytoTrack Business Overview
11.7.3 CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.7.4 CytoTrack Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.7.5 CytoTrack Recent Developments
11.8 Celsee
11.8.1 Celsee Company Details
11.8.2 Celsee Business Overview
11.8.3 Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.8.4 Celsee Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.8.5 Celsee Recent Developments
11.9 Fluxion
11.9.1 Fluxion Company Details
11.9.2 Fluxion Business Overview
11.9.3 Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.9.4 Fluxion Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.9.5 Fluxion Recent Developments
11.10 Gilupi
11.10.1 Gilupi Company Details
11.10.2 Gilupi Business Overview
11.10.3 Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.10.4 Gilupi Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.10.5 Gilupi Recent Developments
11.11 Cynvenio
11.11.1 Cynvenio Company Details
11.11.2 Cynvenio Business Overview
11.11.3 Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.11.4 Cynvenio Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.11.5 Cynvenio Recent Developments
11.12 On-chip
11.12.1 On-chip Company Details
11.12.2 On-chip Business Overview
11.12.3 On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.12.4 On-chip Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.12.5 On-chip Recent Developments
11.13 YZY Bio
11.13.1 YZY Bio Company Details
11.13.2 YZY Bio Business Overview
11.13.3 YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.13.4 YZY Bio Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.13.5 YZY Bio Recent Developments
11.14 BioView
11.14.1 BioView Company Details
11.14.2 BioView Business Overview
11.14.3 BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.14.4 BioView Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.14.5 BioView Recent Developments
11.15 Fluidigm
11.15.1 Fluidigm Company Details
11.15.2 Fluidigm Business Overview
11.15.3 Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.15.4 Fluidigm Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.15.5 Fluidigm Recent Developments
11.16 Ikonisys
11.16.1 Ikonisys Company Details
11.16.2 Ikonisys Business Overview
11.16.3 Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.16.4 Ikonisys Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.16.5 Ikonisys Recent Developments
11.17 AdnaGen
11.17.1 AdnaGen Company Details
11.17.2 AdnaGen Business Overview
11.17.3 AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.17.4 AdnaGen Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.17.5 AdnaGen Recent Developments
11.18 IVDiagnostics
11.18.1 IVDiagnostics Company Details
11.18.2 IVDiagnostics Business Overview
11.18.3 IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.18.4 IVDiagnostics Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.18.5 IVDiagnostics Recent Developments
11.19 Miltenyi Biotec
11.19.1 Miltenyi Biotec Company Details
11.19.2 Miltenyi Biotec Business Overview
11.19.3 Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.19.4 Miltenyi Biotec Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.19.5 Miltenyi Biotec Recent Developments
11.20 ScreenCell
11.20.1 ScreenCell Company Details
11.20.2 ScreenCell Business Overview
11.20.3 ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.20.4 ScreenCell Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.20.5 ScreenCell Recent Developments
11.21 Silicon Biosystems
11.21.1 Silicon Biosystems Company Details
11.21.2 Silicon Biosystems Business Overview
11.21.3 Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.21.4 Silicon Biosystems Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.21.5 Silicon Biosystems Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Janssen
Qiagen
Advanced Cell Diagnostics
ApoCell
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Fluidigm
Ikonisys
AdnaGen
IVDiagnostics
Miltenyi Biotec
ScreenCell
Silicon Biosystems
听
听
*If Applicable.
